Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.82 EUR | +0.54% | +4.66% | +50.92% |
11/04 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
08/04 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Sales 2024 * | 2.62M 2.8M 234M | Sales 2025 * | 2.11M 2.26M 189M | Capitalization | 932M 997M 83.16B |
---|---|---|---|---|---|
Net income 2024 * | -160M -171M -14.27B | Net income 2025 * | -165M -176M -14.72B | EV / Sales 2024 * | 322 x |
Net cash position 2024 * | 87.4M 93.45M 7.79B | Net cash position 2025 * | 44.68M 47.77M 3.98B | EV / Sales 2025 * | 420 x |
P/E ratio 2024 * |
-5.79
x | P/E ratio 2025 * |
-5.46
x | Employees | 61 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.25% |
Latest transcript on Abivax
1 day | +0.54% | ||
1 week | +4.66% | ||
Current month | +10.60% | ||
1 month | +11.09% | ||
3 months | +27.54% | ||
6 months | +68.41% | ||
Current year | +50.92% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 66 | 05/23/05 | |
Didier Blondel
DFI | Director of Finance/CFO | - | 02/17/02 |
Sheldon Sloan
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 65 | 04/13/04 | |
Kinam Hong
BRD | Director/Board Member | - | - |
Troy Ignelzi
BRD | Director/Board Member | 56 | 11/23/11 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 14.82 | +0.54% | 13,478 |
25/24/25 | 14.74 | -2.38% | 8,287 |
24/24/24 | 15.1 | -0.53% | 13,743 |
23/24/23 | 15.18 | +5.42% | 27,184 |
22/24/22 | 14.4 | +1.69% | 16,003 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+50.92% | 995M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABVX Stock